Bile acids have been implicated in biliary tract
carcinogenesis, in part, by activating the
epidermal growth factor receptor (EGFR). Overexpression of Mcl-1, a potent antiapoptotic
protein of the Bcl-2 family, has also been reported in
cholangiocarcinomas. Because
receptor tyrosine kinases like EGFR may modulate antiapoptotic
protein expression, we examined the hypothesis that
bile acids modulate Mcl-1 expression levels via EGFR.
Deoxycholate increased cellular Mcl-1
protein in a concentration-dependent manner. The
deoxycholate-mediated increase of cellular Mcl-1
protein was blocked equally by EGFR
tyrosine kinase inhibitors or an EGFR-
neutralizing antibody. Although inhibition of
mitogen-activated protein kinases did not attenuate the
deoxycholate-associated increase in Mcl-1
protein, the Raf-1 inhibitor, BAY 37-9751, effectively blocked the cellular increase of this
protein. Neither Mcl-1 transcriptional activity nor its mRNA stability was altered by
deoxycholate treatment. However, Mcl-1 protein stability was increased by
bile acid treatment, an effect duplicated by
proteasome inhibition.
Deoxycholate prolongation of Mcl-1 turnover was blocked by either EGFR inhibitors or the Raf-1 inhibitor. Whereas the
deoxycholate-induced increase in Mcl-1 reduced Fas-mediated apoptosis, the Raf-1 inhibitor potentiated Fas apoptosis. Our results demonstrate that
bile acids block Mcl-1 protein degradation via activation of an EGFR/Raf-1 cascade resulting in its cellular accumulation. Raf-1 inhibitors block this increase of Mcl-1 and render the cells more susceptible to apoptosis, a potential therapeutic strategy for
cholangiocarcinomas.